Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:FNB
NYSE:FNBBanks

Assessing F.N.B Corporation (FNB) Valuation After Dividend Hike And $250 Million Buyback Authorization

Why F.N.B (FNB) is in focus today F.N.B (FNB) is back on investors' radar after its Board approved an 8% lift in the quarterly dividend to $0.13 per share and authorized a new $250 million share repurchase program. See our latest analysis for F.N.B. The dividend and buyback news comes after a period of steady share price gains, with a 30 day share price return of 11.6% and a 1 year total shareholder return of 50.8%. This suggests momentum has been building rather than fading. If this kind of...
NYSE:CCL
NYSE:CCLHospitality

Is It Too Late To Consider Carnival (CCL) After Its Strong Share Price Recovery?

Wondering whether Carnival Corporation & at around US$28.82 is still good value after its recovery, or if most of the upside is already priced in. The stock price has moved 2.8% over the last 7 days and 16.6% over the last 30 days, with a 1 year return of 62.0% and a 3 year return of around 195.4%, even as year to date performance sits at a 6.8% decline and the 5 year return is 5.9%. Recent headlines have focused on Carnival Corporation & as a key name in the cruise sector recovery story,...
NasdaqGS:STOK
NasdaqGS:STOKBiotechs

Did Stoke's New R&D Chair Appointment Just Reshape Stoke Therapeutics' (STOK) Antisense Strategy Priorities?

Earlier in April 2026, Stoke Therapeutics expanded its Board of Directors to ten members and appointed G. Clare Kahn, Ph.D., a veteran of Pfizer, GlaxoSmithKline and X-VAX, as a Class I director and chair of the Board’s Research and Development Committee. Her combination of deep regulatory, preclinical and lifecycle management experience could meaningfully influence how Stoke prioritizes and advances its antisense pipeline for severe genetic diseases. Next, we’ll consider how Dr. Kahn’s...
NasdaqGS:IREN
NasdaqGS:IRENSoftware

A Look At IREN (NasdaqGS:IREN) Valuation After Its Recent Share Price Surge

What recent performance says about IREN Without a single headline event driving attention, IREN (NasdaqGS:IREN) has still caught investor interest after a 3.1% move in the latest session and a 32.6% gain over the past week. See our latest analysis for IREN. The recent 32.6% 7 day share price return comes after a quieter 1 month share price move of 8.6%. The 1 year total shareholder return is roughly 8x and the 3 year total shareholder return is a little above 10x, which hints that momentum...
OM:DUST
OM:DUSTElectronic

Dustin Group (OM:DUST) Near Breakeven EPS Loss In Q2 2026 Challenges Prolonged Bearish Narratives

Dustin Group (OM:DUST) has put fresh numbers on the table for Q2 2026, with quarterly revenue of SEK5.5 billion and a basic EPS loss of SEK0.02, while the trailing 12 month figures show revenue of SEK21.1 billion and a basic EPS loss of SEK2.46. Over the past reported periods, quarterly revenue has moved in a relatively tight band between SEK4.8 billion and SEK5.5 billion, while basic EPS has ranged from a small profit of SEK0.00 to a much wider loss of SEK5.59. This keeps margins clearly in...
NYSE:FLR
NYSE:FLRConstruction

How Investors May Respond To Fluor (FLR) Winning New US Refinery and Advanced Nuclear Contracts

Fluor Corporation recently announced two new US energy assignments: front-end engineering and design for America First Refining’s planned large-scale Brownsville, Texas refinery, and FEL-2 services for X-energy’s advanced nuclear project at Dow’s Seadrift operations, with both undisclosed contracts to be recognized in first-quarter 2026. These wins highlight Fluor’s dual role in supporting conventional fuels and advanced nuclear power, reinforcing its position across diverse US energy...
XTRA:CBK
XTRA:CBKBanks

Commerzbank Crypto Push And Independence Case Tested Against Valuation Story

Commerzbank (XTRA:CBK) is moving into crypto services under the EU's new MiCA regulation, alongside other major German banks. The move comes shortly after Commerzbank's board rejected a takeover approach from UniCredit, confirming its plan to remain independent. These decisions highlight a shift in Commerzbank's business focus beyond traditional banking activities. For investors watching XTRA:CBK, this new crypto push arrives as the shares trade at about €35.29. The stock has seen a 56.3%...
OB:PEXIP
OB:PEXIPSoftware

Undiscovered European Gems with Strong Potential April 2026

As European markets experience a rally, with the STOXX Europe 600 Index up 3.05% following a U.S.-Iran ceasefire, investors are cautiously optimistic despite looming economic uncertainties like potential stagflation and revised growth forecasts. In this environment, identifying stocks that exhibit resilience and adaptability to shifting geopolitical and economic landscapes can be crucial for navigating the complexities of the current market.
XTRA:BST
XTRA:BSTMedia

3 European Dividend Stocks With Up To 5.9% Yield

As European markets rally following a U.S.-Iran ceasefire, investors are increasingly focusing on opportunities that offer both stability and income in the form of dividends. In such an environment, dividend stocks can be appealing for their potential to provide steady returns amidst economic uncertainties.
NYSE:STWD
NYSE:STWDMortgage REITs

A Look At Starwood Property Trust (STWD) Valuation As Opinions On Its True Worth Diverge

Why Starwood Property Trust Is on Investors’ Radar Today Starwood Property Trust (STWD) is drawing fresh attention after its recent trading performance, with the stock showing mixed short term moves, alongside a positive 1 year total return and multi year total returns that some income investors are reviewing closely. See our latest analysis for Starwood Property Trust. At a share price of $18.15, the stock has seen a 3.5% 1 month share price return and a modest year to date share price...
NasdaqGS:CME
NasdaqGS:CMECapital Markets

Does New Eris SOFR Swap Options Launch Reshape the Bull Case For CME Group (CME)?

CME Group has announced it will launch options on Eris SOFR Swap futures on June 16, 2026, pending regulatory review, adding options on 2-year, 5-year and 10-year contracts that are designed to replicate interest rate swap cash flows while offering margin offsets with other cleared interest rate products at CBOT. This expansion builds on growing use of Eris SOFR Swap futures, which have surpassed 10 million contracts traded and set an all-time open interest record of 707,000 contracts, and...
NYSE:OVV
NYSE:OVVOil and Gas

A Look At Ovintiv (OVV) Valuation As Analysts See Shares Modestly Undervalued

Ovintiv (OVV) has drawn fresh attention after recent trading left the stock at $55.04, with a value score of 6 and a market cap near US$15.5b, prompting closer scrutiny from income- and value-focused investors. See our latest analysis for Ovintiv. Recent trading has been choppy, with a 1-day share price return of 0.44% and a 7-day share price return of negative 3.06%, set against a stronger 90-day share price return of 37.77% and a 1-year total shareholder return of 70.93%. This points to...
NasdaqCM:SEZL
NasdaqCM:SEZLDiversified Financial

Sezzle’s Canadian Virtual Card Tests BNPL Growth And Risk Control

Sezzle (NasdaqCM:SEZL) has launched its Virtual Card in Canada, powered by Marqeta. The roll out extends Sezzle’s Buy Now, Pay Later offering to a new geography and broadens where consumers can use the service. This move opens additional opportunities for participating merchants to offer installment payments at more checkout locations. For readers tracking the Buy Now, Pay Later space, this Canadian launch gives more detail on how Sezzle is building out its product set and footprint. The...
NasdaqGS:ADBE
NasdaqGS:ADBESoftware

Adobe Firefly AI Assistant Aims To Deepen Creative Suite Engagement For Investors

Adobe has launched Firefly AI Assistant, a unified conversational interface that brings AI guided creative workflows into its core applications. The new assistant lets users trigger multi step creative tasks using natural language, with context aware support across multiple Adobe apps. The release also includes deeper integrations with third party AI models and expanded Firefly tools for image and video editing. Adobe (NasdaqGS: ADBE) is rolling out Firefly AI Assistant as it trades around...
ENXTPA:ELIS
ENXTPA:ELISCommercial Services

Is Elis (ENXTPA:ELIS) Price Still Reasonable After Strong Multi‑Year Share Gains?

Wondering if Elis at €26.22 is offering fair value or if the recent price is leaving too much on the table? This article breaks down what the current market price might be implying about the business. Elis has returned 0.7% over the last week, 2.5% over the last month, 10.1% year to date, 24.6% over 1 year, 58.6% over 3 years, and 95.1% over 5 years, which may prompt you to ask whether the recent share price still lines up with the fundamentals. Recent news coverage has focused on Elis as a...
NYSE:AGCO
NYSE:AGCOMachinery

Is It Time To Reassess AGCO (AGCO) After Its Recent Share Price Pullback?

If you are wondering whether AGCO at around US$115 is still offering value after a strong run, the key is to look past the headline share price and focus on what the numbers say about valuation. The stock has eased back with a 3.9% decline over the last 7 days and a 2.8% decline over the last 30 days, although it still shows a 45.1% return over the past year and an 8.9% gain year to date. Recent coverage has focused on AGCO's role within the wider capital goods sector and how investors are...
BME:ALM
BME:ALMPharmaceuticals

Almirall Taps Supercomputing And AI As Dermatology Returns Draw Focus

Almirall has expanded its collaboration with the Barcelona Supercomputing Center to advance research in medical dermatology using supercomputing and artificial intelligence. The company has joined the BSC Connects program, gaining access to advanced computational tools, research support, and tailored training. The development focuses on strengthening Almirall’s dermatology R&D pipeline and future drug discovery capabilities. For investors tracking BME:ALM, the company is trading at €13.08...
NasdaqGS:MSTR
NasdaqGS:MSTRSoftware

Is It Time To Revisit MicroStrategy (MSTR) After Its Sharp One Year Pullback?

This article focuses on what the current price of Strategy might be indicating for investors who are wondering whether it is starting to look undervalued or whether the recent volatility is a warning sign. The stock recently closed at US$143.54, with returns of 11.9% over the last 7 days, a 2.7% decline over 30 days, an 8.7% decline year to date, a 53.9% decline over 1 year, and very large gains over 3 and 5 years. Recent coverage has focused on Strategy's sharp pullback over the past year...